Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer-peptide conjugates

被引:25
作者
Ding, H
Prodinger, WM
Kopecek, J [1 ]
机构
[1] Univ Utah, Dept Pharmaceut, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Pharmaceut Chem, Salt Lake City, UT 84112 USA
[3] Innsbruck Med Univ, Dept Hyg Microbiol & Social Med, Innsbruck, Austria
关键词
D O I
10.1021/bc0503162
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Cancer targeting with peptides has become promising with the emergence of combinatorial peptide techniques such as phage display. Using phage display under stringent screening conditions, we selected five distinct peptides that specifically recognized the CD21 receptor, a cell surface marker of malignant B cell lymphoma. Two highly hydrophobic sequences were excluded (RLAYWCFSGLFLLVC and PVAAVSFVPYLVKTY). The binding affinity toward CD21 of the other three selected peptides (RMWPSSTVNLSAGRR, PNLDFSPTCSFRFGC, and GRVPSMFGGHFFFSR) was analyzed with fluorescence quenching. Their dissociation constants were determined to be within the micromolar range. On the basis of the results of phage ELISA, competitive phage ELISA, and fluorescence quenching, the binding sites of the three selected peptides were found to reside within the first four short consensus repeats of CD21 (SCRI-4). The peptide RMWPSSTVNLSAGRR (P1) was bound to the N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer, a potential drug carrier for chemotherapeutic agents, and the surface binding properties of HPMA copolymer-P1 conjugates were investigated. Specific interactions were observed between HPMA copolymer-P1 conjugates and surface-bound receptor. Binding of HPMA copolymer-P1 conjugates was directly related to the amount of surface (MaxiSorp plate) bound receptor, and the binding of the conjugates could be inhibited by the application of a 3-4 orders-of-magnitude excess of free peptide over the peptide concentration in conjugates. The enhanced binding of polymer-bound peptide was ascribed to multivalent interactions between the HPMA copolymer-P1 conjugate and the surface-bound CD21 receptor.
引用
收藏
页码:514 / 523
页数:10
相关论文
共 54 条
[1]   Monoclonal antibody therapy of cancer [J].
Adams, GP ;
Weiner, LM .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157
[2]   Therapeutic cancer targeting peptides [J].
Aina, OH ;
Sroka, TC ;
Chen, ML ;
Lam, KS .
BIOPOLYMERS, 2002, 66 (03) :184-199
[3]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[4]   POLY[N-(2-HYDROXYPROPYL)METHACRYLAMIDE] .2. HYDRODYNAMIC PROPERTIES OF DILUTE-SOLUTIONS [J].
BOHDANECKY, M ;
BAZILOVA, H ;
KOPECEK, J .
EUROPEAN POLYMER JOURNAL, 1974, 10 (05) :405-410
[5]   EPSTEIN-BARR-VIRUS (EBV) INDUCES EXPRESSION OF B-CELL ACTIVATION MARKERS ON INVITRO INFECTION OF EBV-NEGATIVE B-LYMPHOMA CELLS [J].
CALENDER, A ;
BILLAUD, M ;
AUBRY, JP ;
BANCHEREAU, J ;
VUILLAUME, M ;
LENOIR, GM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) :8060-8064
[6]   Monoclonal antibodies in the treatment of cancer, part 1 [J].
Cersosimo, RJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (15) :1531-1548
[7]   Monoclonal antibodies in the treatment of cancer, part 2 [J].
Cersosimo, RJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (16) :1631-1641
[8]   Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library [J].
Chen, YCJ ;
Delbrook, K ;
Dealwis, C ;
Mimms, L ;
Mushahwar, IK ;
Mandecki, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) :1997-2001
[9]   Functional properties of soluble CD21 [J].
Frémeaux-Bacchi, V ;
Kolb, JP ;
Rakotobé, S ;
Kazatchkine, MD ;
Fischer, EM .
IMMUNOPHARMACOLOGY, 1999, 42 (1-3) :31-37
[10]  
Friedberg Jonathan W, 2004, Expert Rev Anticancer Ther, V4, P18, DOI 10.1586/14737140.4.1.18